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SUMMARY
The relationship between heme metabolism and angiogenesis is poorly under-
stood. The final synthesis of heme occurs in mitochondria, where ferrochelatase
(FECH) inserts Fe2+ into protoporphyrin IX to produce proto-heme IX. We pre-
viously showed that FECH inhibition is antiangiogenic in human retinal micro-
vascular endothelial cells (HRECs) and in animal models of ocular neovasculariza-
tion. In the present study, we sought to understand the mechanism of how
FECH and thus heme is involved in endothelial cell function. Mitochondria in
endothelial cells had several defects in function after heme inhibition. FECH
loss changed the shape and mass of mitochondria and led to significant oxida-
tive stress. Oxidative phosphorylation and mitochondrial Complex IV were
decreased in HRECs and in murine retina ex vivo after heme depletion. Supple-
mentation with heme partially rescued phenotypes of FECH blockade. These
findings provide an unexpected link between mitochondrial heme metabolism
and angiogenesis.
INTRODUCTION
An imbalance in mitochondrial metabolism has been implicated in the development of neovascular dis-
eases catalyzed by aberrant angiogenesis. However, the role of heme synthesis in the development of
mitochondrial dysfunction in neovascular diseases is unclear.
Neovascularization is a common phenomenon seen in vascular diseases like cancer, type 2 diabetes melli-
tus, proliferative diabetic retinopathy (PDR), wet age-related macular degeneration (AMD), and retinop-
athy of prematurity (ROP) (Friedman et al., 2004; Hellstrom et al., 2013; Kempen et al., 2004; Kizhakekuttu
et al., 2012). Neovascularization is the disease process where new blood vessels grow from pre-existing
ones, and in the eye this can contribute to ocular complications like hemorrhages, retinal detachment,
and loss of central vision (Campochiaro, 2013). Endothelial cells (ECs) are key to this process, mediating
different cellular functions essential for angiogenesis like proliferation, migration, and vascular perme-
ability (Vandekeere et al., 2015).
We previously reported that heme synthesis inhibition is anti-angiogenic in retinal ECs in vitro and in animal
models of ocular neovascularization. Blocking heme production in human retinal microvascular ECs
(HRECs) decreased proliferation, migration, and endothelial tube formation and caused reduced protein
expression of total and phosphorylated VEGF receptor 2 (Basavarajappa et al., 2017). This antiangiogenic
effect was only seen in ocular ECs, whereas ocular non-endothelial cells were not similarly affected. Heme
synthesis inhibition was associated with smaller ocular neovascular lesions in choroidal and retinal neovas-
cularization mouse models (Basavarajappa et al., 2017; Pran Babu et al., 2020). However, the mechanism
underlying this effect remains unknown.
The final synthesis of heme takes place in the mitochondria, when ferrochelatase (FECH) inserts ferrous ion
into a precursor protoporphyrin IX (PPIX) to form protoheme (iron-protoporphyrin IX) (Dailey et al., 2017;
Nilsson et al., 2009; Poulos, 2014). By directly targeting FECH, cells can be depleted of heme and heme-
containing proteins, with a concomitant buildup of PPIX (Atamna et al., 2001; Vijayasarathy et al., 1999).
Apart from the role of heme in oxygen transport and storage, heme acts as a prosthetic group in many
hemoprotein enzymes involved in oxidative phosphorylation, plus cytochrome P450s, catalases, and nitric
oxide synthase (Chiabrando et al., 2014).
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In the present study, we aimed to assess the relationship between mitochondrial physiology in human ECs
and heme inhibition. We hypothesized that heme inhibition would lead to defects in heme-containing en-
zymes of the mitochondrial electron transport chain (ETC) and thus affect mitochondrial function of ECs.
We show that loss of heme altered mitochondrial morphology and dynamics, causing increased reactive
oxygen species (ROS) levels and depolarized membrane potential. Our studies reveal that heme synthesis
is required for EC respiration and complex IV (cytochrome c oxidase; CcO) function specifically and can
negatively impact glycolytic capacity of ECs. Thus, we characterize a previously unknown role of heme in
cellular metabolism that facilitates EC function in angiogenesis.
RESULTS
Heme Inhibition Caused Changes to Mitochondrial Morphology and Increased Oxidative
Stress
To block heme production, we used a competitive inhibitor of FECH, the terminal enzyme responsible for
catalyzing heme synthesis (Shi and Ferreira, 2006) (see Transparent Methods). Blockade of FECHwith active
site inhibitor N-methylprotoporphyrin (NMPP) causes accumulation of precursor PPIX (Figure S1A). HRECs
treated with NMPP showed changes in mitochondrial fragmentation and shape (Figure 1A). NMPP-treated
cells had decreased form factor values, indicating reduced mitochondrial branching (Figures 1B and S1B–
S1G), owing tomore highly fragmentedmitochondria (Figure 1A, inset image). Mitochondria appeared less
elongated and elliptical in NMPP-treated HRECs as seen by lower aspect ratio values (Figure 1C). To deter-
mine mitochondrial mass, we used flow cytometry and quantified median fluorescence intensity (MFI) of
NMPP-treated HRECs (Doherty and Perl, 2017). NMPP treatment led to reducedMFI, indicating decreased
mass in mitochondria (Figure 1D).
We tested mRNA levels of key mitochondrial fusion proteins involved in mitochondrial dynamics, MFN2
and OPA1, and found significantly lower levels under FECH blockade conditions (Figures 1E and 1F).
Fission regulator DNM1L (encoding Drp1) showed no change. We measured mitochondrial-specific ROS
using MitoSox ROS, and cells treated with NMPP showed a marked increase in ROS levels (Figure 1G).
We quantified this increase using flow cytometry and found a significant increase in MitoSox ROS-labeled
HRECs treated with NMPP (Figures 1H and 1I). This effect of elevated ROS levels was also seen in RF/6A
cells treated with NMPP (Figures S4A and S4B). This primate cell line has properties of chorioretinal ECs
(Lou and Hu, 1987) and thus provides corroboration of the primary HREC data.
Loss of FECH Depolarized Mitochondrial Membrane Potential
To assess mitochondrial health, we next measured membrane potential using JC-1, a polychromatic dye
that on excitation forms red aggregates and greenmonomers depending on the energized or deenergized
state of mitochondria. Both siRNA-mediated knockdown of FECH and chemical inhibition using NMPP
induced loss of healthy red aggregates and an increase in monomers as seen by the green fluorescence
(Figures 2A and 2D). This JC-1 excitation was quantified using flow cytometry on HRECs labeled with
JC-1 dye and showed reduced red to green fluorescence ratio, indicative of mitochondrial depolarization
(Figures 2B, 2C, 2E, and 2F). RF/6A cells also showed depolarized membrane potential after NMPP treat-
ment (Figures S4C–S4E).
Reduced CcO Expression and Activity Rescued by Hemin
To determine where heme depletion was influencing mitochondrial function, we evaluated protein com-
plexes of the ETC after heme inhibition, as complexes II, III, and IV contain heme in their prosthetic groups
(Kim et al., 2012). FECH knockdown resulted in a significant decrease of only CcO (Figures 3A and 3B).
NMPP-treated cells showed a similar decrease in CcO, and we also found increased expression of Complex
V (ATP synthase) upon treatment with this small molecule (Figures 3A and 3C). Additionally, we also as-
sessed mRNA expression of ETC complex genes, NDUFS1 (complex I), SDHA (complex II), UQCRQ (com-
plex III),MT-CO1 (mitochondrially encoded CcO subunit 1), and COX4I1 (nuclear encoded CcO subunit 1).
Only the nuclear-encoded CcO gene showed a significant decrease in mRNA expression (Figure S5A). We
then examined the protein levels of heme-containing subunit 1 of CcO (COX4I1) and found a significant
decrease under both knockdown and NMPP treatment (Figures 3D–3G). Enzyme activity of CcO was
also reduced, and total levels of the complex were significantly reduced after FECH blockade (Figures
3H–3K). Moreover, enzyme activities of complexes I–III remained unaffected (Figures S5B–S5D). To confirm
if our results were dependent on heme, we sought to rescue the phenotype of CcO reduction by external
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Figure 1. FECH Blockade Altered Mitochondrial Morphology and Increased Oxidative Stress
(A–C) (A) HRECs treated with DMSO or FECH inhibitor NMPP stained with MitoTracker green (MTG). Inset images
indicate magnified region marked in red boxes. Form factor (B) and aspect ratio (C) as quantified using ImageJ. Individual
data points indicate mean of mitochondria analyzed from each of 12 individual cells per treatment group.
(D–F) (D) Quantification of MTG fluorescence using flow cytometry and calculated median fluorescence intensity (MFI).
qPCR analysis of mRNA expression under FECH knockdown (E) or NMPP treatment (F).
(G) HRECs stained with mitoSox ROS in red and Hoechst staining in blue.
(H and I) (H) Representative fluorescence peaks as measured by flow cytometry followed by (I) quantification of cells
positive for red fluorescence.
Bar graphs indicate meanG SEM, n = 3. Representative results from three independent experiments. ns, non-significant, *p <
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, two-tailed unpaired Student’s t test. Scale bars, 20 mm. See also Figures S1 and S4.
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supplementation of heme to the cells. Hemin, a stable form of heme, was able to alleviate CcO protein
expression depletion and partially rescue CcO enzyme activity (Figures 3L–3N). RF/6A cells showed a
similar rescue phenotype of CcO enzyme after heme addition (Figures S6A–S6D). We also used another
heme synthesis inhibitor, succinylacetone, which blocks the second committed enzyme in heme synthesis,
5-aminolevulinic acid dehydratase (ALAD), upstream of the PPIX-FECH step (Dailey et al., 2017; Vande-
keere et al., 2018). HRECs treated with succinylacetone showed reduction in protein expression of CcO
and also Complex III (Figures S7A and S7B).
Figure 2. Loss of FECH Reduced Mitochondrial Membrane Potential in HRECs
(A–F) HRECs stained with JC-1 dye showing green monomers and red aggregates under FECH knockdown condition (A)
and NMPP treatment (D). Representative dot plots of FL1 versus FL2 channel from three individual experiments,
measuring red and green fluorescence using flow cytometry after FECH knockdown (B) and NMPP treatment (E). Red and
green arrows indicate quadrants expressing FL1-red and FL2-green fluorescent cells. (C and F) Quantification of
red:green fluorescence from flow experiment. Bar graphs indicate mean G SEM, n = 3; ns, non-significant, *p < 0.05,
***p < 0.001, one-way ANOVA with Tukey’s post hoc tests. Scale bars, 20 mm. See also Figure S4.
ll
OPEN ACCESS
4 iScience 23, 101391, August 21, 2020
iScience
Article
FECH Blockade Reduced Mitochondrial Function of Retinal ECs
To understand whether loss of function of an important complex in the ETC resulted in defects in mitochon-
drial respiration, we assessed maximal oxygen consumption rate (OCR) induced by the potential gradient
uncoupler FCCP (Figures S2A and S2B). FCCP induces uninhibited flow of electrons across the ETC,
causing the enzymes of the respiratory chain to use metabolic substrates at full potential and, in turn,
Figure 3. FECH Inhibition Caused Reduced CcO Expression, Rescued by Hemin
(A) HRECs under FECH siRNA or NMPP-treated conditions were immunoblotted for Complexes I–V as indicated.
(B and C) Quantification of the blots was graphed as shown relative to appropriate control.
(D) FECH siRNA-treated HRECs were probed for CcO nuclear encoded subunit 1 (COX4I1) and FECH along with
housekeeping control and (E) quantified. Similarly, HRECs treated with NMPP were blotted for CcO subunit 1 (F) with (G)
quantification as shown. CcO enzyme activity was measured under FECH knockdown condition (H) and NMPP treatment
(J) and total CcO levels were quantified by ELISA for both the conditions (I and K).
(L and M) CcO protein expression and quantification under defined conditions.
(N) CcO enzyme activity was partially rescued in NMPP-treated cells exposed to hemin. Immunoblot images
representative from three independent experiments.
Bar graphs indicate mean G SEM, n = 3–4; ns, non-significant, *p < 0.05, **p < 0.01, ****p < 0.0001. (B, C, E, G, H–K)
unpaired Student’s t test (M and N) one-way ANOVA with Tukey’s post hoc tests. See also Figures S5–S7.
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revealing the maximal cellular capacity that can meet energy demands under metabolically stressed con-
ditions (Dranka et al., 2011). Under metabolic stress, both HRECs and RF/6A cells underwent increased
glycolysis to meet energy demands (Figures S2C–S2F).
Based on these optimized parameters (Figure S3), wemeasured OCR of HRECs after FECH knockdown and
observed reduced basal respiration (Figures 4A and 4B). Uncoupler-induced maximal respiration was
significantly decreased, with a marked reduction also found in OCR-linked ATP production and spare res-
piratory capacity (Figures 4C–4E). Similarly, NMPP treated cells showed a dose-dependent decrease in
basal (Figures 4F and 4G) and maximal respiration (Figure 4H) along with a decline in OCR-linked ATP pro-
duction and spare respiratory capacity (Figures 4I and 4J). We saw a similar decrease in mitochondrial
respiratory activity in RF/6A cells (Figures S6E–S6I). Succinylacetone-treated HRECs also showed a
decrease in basal and maximal respiration along with reduced OCR-linked ATP production and spare
respiratory capacity (Figures S7C–S7G).
Inhibition of FECH Led to Decreased Glycolytic Function
Microvascular ECs are highly glycolytic compared with other cell types (De Bock et al., 2013). Under mito-
chondrial stress, both HREC and RF/6A cells had increased glycolysis over mitochondrial respiration in our
system (Figures S2C–SF). Hence, we next investigated this key cellular energetic pathway in HRECs by
measuring changes in the pH of the extracellular medium. Cells were briefly starved in glucose-deficient
medium, followed by induction of glycolysis using a saturating dose of glucose. Interestingly, HRECs under
siRNA-mediated FECH knockdown and NMPP treatment each had decreased glycolytic capacity and
glycolysis (Figures 5A–5C and 5E–5G). Both conditions depleted glycolytic reserve, as seen by a marked
decrease in ECAR after 2-DG injection (Figures 5D and 5H).
FECH Inhibition In Vivo Caused Impaired Mitochondrial Energetics in Retina
We further determined if the effect of NMPP had the same phenotype in vivo in an intact eye. For this, we
administered NMPP intravitreally to mice and measured OCR of retina in an ex vivo assay (Figure 6A). We
found that retinas treated with NMPP had a significant decrease in basal respiration and a similar decline in
maximal respiration (Figures 6B and 6C). Spare respiratory capacity was severely reduced in the retinas of
NMPP-treated animals compared with their vehicle-treated counterparts (Figure 6D). We also observed
about a 30% reduction in protein expression of subunit 1 of CcO in the NMPP-treated retinas (Figures
6E and 6F).
DISCUSSION
Heme synthesis blockade suppresses pathological angiogenesis by poorly understood mechanisms. In the
present study, we sought to investigate the effects of heme inhibition on the mitochondrial function of
retinal ECs by directly studying heme-containing complexes of the ETC and documenting mitochondrial
physiology under heme depletion.
The mitochondrial ETC is a major source of ROS induced by vascular endothelial growth factor (VEGF) in
hyperglycemic and hypoxic cellular environments (Cheng et al., 2011; Pearlstein et al., 2002; Wang et al.,
2018). In PDR, increasedmitochondrial ROS and impaired Ca2+ signaling can cause an increase in oxidative
stress (Kowluru andMishra, 2015; Pangare andMakino, 2012; Tang et al., 2014; Wang et al., 2018). Complex
III of the ETC was recently shown to be important for umbilical vein EC respiration and thus proliferation
during angiogenesis (Diebold et al., 2019). Mitochondrial dysfunction in the retinal pigment epithelium
and photoreceptors has been reported for wet AMD (Barot et al., 2011; Lefevere et al., 2017), but evidence
in retinal ECs is limited. Metabolic factors like succinate and adenosine, generated from the Krebs cycle
and ATP metabolism, respectively, are proangiogenic for hypoxia-driven neovascularization (Sapieha
et al., 2010). However, the exact mechanism of how metabolites disrupt mitochondrial energetics in
ischemic retinal ECs remains unclear (Grant et al., 1999; Sapieha et al., 2008).
Mitochondrial dysfunction in ECs leads to pathological angiogenesis. Heme and heme-containing enzymes
play a significant role in this process, but the linkage between these phenomena has not been extensively
explored. Serine synthesis deficiency induced heme depletion in ECs and caused decreased mitochondrial
respiration andmultiorgan angiogenic defects in animals (Vandekeere et al., 2018), whereas hemeaccumulation
in ECs due to an altered heme exporter affects angiogenesis and causes endoplasmic reticulum stress (Petrillo
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et al., 2018). Apart from ECs, non-small cell lung carcinoma cells with elevated heme synthesis levels had in-
creases in enzyme activities of the ETC. Increased production of heme was associated with increasedmigratory
and invasive properties of these cells and xenograft tumors inmice (Sohoni et al., 2019). Here, we demonstrated
how heme depletion by blockade of the terminal synthesis enzyme FECH led to defects in CcO and ETC
Figure 4. Loss of FECH Reduced Mitochondrial Respiration
(A and F) OCR kinetic traces for HRECs under FECH knockdown or NMPP chemical inhibition.
(B and G) Basal respiration.
(C and H) Maximal respiration.
(D and I) OCR-linked ATP production, and (E and J) spare respiratory capacity were calculated based on OCR curves for
the respective treatment group.
(A and F) Representative OCR curve of three individual experiments. Bar graphs indicate mean G SEM, n = 3; *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001 (B, C, D, and E) unpaired Student’s t test (G, H, I, and J) one-way ANOVA with
Tukey’s post hoc tests. See also Figures S6 and S7.
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disruption (Figure 7). Retinal and choroidal ECs alike have increased mitochondrial-specific oxidative stress,
dysfunctional mitochondrial physiology, and disruption of glycolysis as a result of these defects.
Changes tomitochondrial morphology can indicate alterations inmitochondrial dynamics and cellular function.
Our findings of reduced form factor and aspect ratio after FECH blockade indicate greater fragmentation and
decreased length (Duraisamy et al., 2019; Picard et al., 2013). Furthermore, reduced mitochondrial mass was
evident by our flow cytometric analysis. HRECs after heme depletion also had reduced MFN2 andOPA1 tran-
script levels. Reduction of these mitochondrial fusion protein marker genes confirms a change in mitochondrial
dynamics. An increase in fragmented mitochondria also leads to increased ROS levels (Jezek et al., 2018), as
confirmed by our results. Moreover, disruption of fusion proteins can also lead to an increase in ROS levels
Figure 5. FECH Inhibition Caused a Decrease in Glycolytic Function
(A–H) (A and E) ECAR kinetic traces for HRECs under FECH knockdown or NMPP chemical inhibition. (B and F) Glycolysis,
(C and G) glycolytic capacity, and (D and H) glycolytic reserve were calculated based on ECAR curves for the respective
treatment group.
(A and E) Representative ECAR curve of three individual experiments. Bar graphs indicate meanG SEM, n = 3; **p < 0.01,
***p < 0.001, ****p < 0.0001, unpaired Student’s t test. 2-DG, 2-deoxyglucose.
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(Kim et al., 2018), as also evident in our cell model. Although we did not observe any change in fission protein
expression, decreasedMFN2 is also consistent with the smaller, fragmentedmitochondria we observed, similar
to those seen in diabetic mouse coronary ECs (Makino et al., 2010).
Inner mitochondrial membrane potential (DJm) was considerably decreased after FECH knockdown or
NMPP treatment. This finding was explained by our result of reduced CcO expression and activity, which
might have collapsed the potential gradient and caused a reduced membrane potential. Our mitochon-
drial energetics findings further support this result. A significant reduction in FCCP-inducedmaximal respi-
ration indicates defective CcO, which is unable to perform the role of electron transfer. Uncoupling brought
on by FCCP causes the ETC to rely on CcO to carry out oxidative phosphorylation by the free-flowing elec-
trons (Dranka et al., 2011). Under FECH inhibition conditions, FCCP-induced maximal respiration was
affected, indicating CcO dysfunction due to heme loss.
Figure 6. FECH Inhibition In Vivo Decreased Mitochondrial Respiration in Retina
(A) Representative OCR kinetic traces for retina from animals treated with NMPP.
(B–D) (B) Basal respiration, (C) maximal respiration, and (D) spare respiratory capacity were calculated based on OCR
curves for the respective treatment groups.
(E) Immunoblot showing CcO nuclear encoded subunit 1 (COX4I1) protein expression from three pooled retinal tissue
lysates from NMPP treated eyes and (F) quantification of immunoblots. Graphs indicate mean G SEM for two tissue
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Heme depletion by directly blocking FECH primarily affected levels and activity of CcO of all the other
heme-containing complexes of the ETC in ECs of the retina and choroid. CcO subunit 1 contains heme
a and a3 (not found in complexes I–III and V). Heme a is made in a series of sub-synthesis hemylation steps
carried out by heme a synthase and is essential for proper folding and stability of CcO (Kim et al., 2012)
(Figure 7). CcO is particularly sensitive to FECH inhibition-induced heme depletion, possibly affecting
the hemylation process downstream of protoheme synthesis, leading to a smaller pool of heme a (Atamna
et al., 2001; Sinkler et al., 2017). COX10 and COX15, proteins responsible for conversion of heme b (synthe-
sized by FECH) to heme a were among the top-scoring genes that caused ETC disruption after heme
Figure 7. Schematic Model of Mitochondrial Dysfunction on Heme Loss
Heme synthesis begins with the condensation of glycine and succinyl CoA in the mitochondrial matrix. The final step is the
insertion of ferrous ion into protoporphyrin IX (PPIX), catalyzed by ferrochelatase (FECH) to produce protoheme (also
known as heme b). Protoheme and its derivatives are available for different cellular enzymes, including complexes of the
ETC (e, electrons). Heme a is synthesized by sub-hemylation steps and utilized by CcO (Complex IV) for composition of
the holoenzyme. Heme synthesis blockade by inhibiting the terminal synthesis enzyme FECH leads to CcO defects and
disrupts cellular energetics. Mitochondrial dynamics is altered with reduced fusion and mass, depolarized membrane
potential (DJm) and elevated reactive oxygen species (ROS).
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depletion in acute myeloid leukemia cells (Lin et al., 2019), further suggesting the significance of heme a
supply as a mediator of mitochondrial function, since it is a prosthetic group specifically in CcO holoen-
zyme. Furthermore, blocking the skeletal muscle-specific subunit 7a of CcO decreased mitochondrial
ATP production in mouse hindlimb muscles. Interestingly, this was associated with reduced muscle angio-
genesis and decreased capillarity (Lee et al., 2012), further supporting a link between CcO and EC function.
Our findings on the mRNA and protein levels plus enzyme activities of all ETC complexes are consistent
with this hypothesis that FECH inhibition preferentially disrupts CcO expression and function.
Loss of functional CcO was restored at least partially by extracellular heme supplementation. Additionally,
blocking heme synthesis upstream of FECH by using succinylacetone also led to a similar mitochondrial pheno-
type as FECHblockade. This suggests that the ECphenotype after FECH inhibition is heme dependent and not
due to an off-target effect of NMPP or due to PPIX buildup/toxicity (Wyld et al., 1997). NMPP caused significant
overexpression of complex V (not seen under FECH knockdown), which could be a secondary effect of damage
to CcO, causing compensatory upregulation of ATP synthase (Havlickova Karbanova et al., 2012; Rolland et al.,
2013). Notably, succinylacetone produced a decrease in both Complex III andCcO, perhaps due to amore pro-
found heme synthesis blockade than that achieved by FECH inhibition or knockdown. Our studies previously
reported effects of NMPP and FECH knockdown specific to ECs of retina, choroid, brain, and umbilical vein,
and we did not observe a similar anti-proliferative phenotype on FECH blockade in other ocular cell types of
non-endothelial origin (Basavarajappa et al., 2017). However, the phenotype of FECH deficiency on ETC com-
plexes in other cell types beyond ECs would be an interesting aspect for future exploration.
Perhaps non-endothelial cell types canmeet their energy demands from the glycolysis pathway in the event
of heme depletion-induced ETC dysfunction (Rafikov et al., 2015). Conversely, loss of mitochondrial respi-
ration in ECs due to lack of functional oxidative phosphorylation did not result in compensation by the
glycolysis pathway in ECs (Zielinski et al., 2016). ECs rely upon aerobic glycolysis for nearly 85% of their en-
ergy, a feature that is highly active during aberrant angiogenesis (De Bock et al., 2013). Severe heme deple-
tion could possibly disrupt NADH/H+ and redox homeostasis, as already evident from ETC dysfunction.
Moreover, increased ROS levels in ECs can shift their metabolic needs to accommodate cellular damage
and dysfunction, in which case both cellular energetic systems are collapsed (Vandekeere et al., 2018; War-
ren et al., 2014; Wellen and Thompson, 2010). Interestingly, mitochondrial transcription of CcO subunit 1
(MT-CO1) mRNA is not affected after heme loss (although protein levels were decreased), but the nuclear
encoded CcO gene COX4I1 was significantly decreased at both the mRNA and protein levels after FECH
inhibition. This is in keeping with heme acting at the post-transcriptional level to stabilize the assembly of
the CcO subunits with minimal effect on CcO mitochondrial transcription itself.
In summary, our findings provide a previously unidentified link between heme synthesis, angiogenesis, and
mitochondrial energetics. Specifically, heme synthesis blockade via FECH leads to a reduction in heme availabil-
ity for hemoprotein components of the ETC, notably CcO, likely due to a shortage of heme a and a3. This is then
associated with reduced oxidative phosphorylation, with concomitant loss of mitochondrial membrane poten-
tial and changes inmitochondrial shape anddynamics, aswell as increasedROSproduction (Figure 7). Blockade
of heme during the early stages of the pathway (via ALAD) disrupts heme b synthesis, affecting the ETC proteins
beyond just Complex IV. This potentially explains how ECs rely on a constant supply of heme during increased
energy demands, essential for the formation of neovessels. The role of heme synthesis inmitochondrial function
and pathological angiogenesis has been overlooked. Our observations bridge this gap in knowledge by char-
acterizing the metabolic phenotype of ECs under heme deficiency. Loss of heme provokes prominent anti-
angiogenic effects thatmight be exploited therapeutically for neovascular eye disease.Our findings invite future
studies to further our understanding of metabolic dysfunction in neovascularization.
Limitations of the Study
Retinal ECs are technically laborious for experimental manipulations. Apart from being difficult to transfect,
low absolute heme levels precluded spectral determination of hemes a, b, and c. NMPP as a FECH inhibitor
could be deleterious to other hemoproteins in ECs and could have off-target effects, although we titrated
NMPP to well below toxic levels in these studies and complemented NMPP findings with a knockdown
approach and succinylacetone treatment. Similarly, using hemin to rescue FECH inhibition-induced
heme depletion has limitations. Hemin itself can introduce mitochondrial toxicity (Higdon et al., 2012),
and complete rescue of ETC damage through hemin supplementation is challenging. Additionally, dam-
age to CcO due to insufficient heme could impair formation of ETC supercomplexes (Acin-Perez et al.,
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2008), which was not assessed in our study. Resolving mitochondrial lysates isolated from NMPP-treated
ECs in their endogenous form, for example, by a native gel electrophoresis method, could identify disrup-
tion to the assembly of these complexes (Jha et al., 2016).
Wepreviously tested ageneticmousemodel with aM98Kpointmutation in the Fechgene (Fechm1Pas) leading to
deficiency in FECH activity and found reduced neovascular lesions in the eye (Basavarajappa et al., 2017; Pran
Babu et al., 2020). This Fechm1Pas mouse model shows pronounced PPIX buildup and increased mitochondrial
respiratory activity, specifically CcO (Navarro et al., 2005), likely a compensatory response to constitutive heme
depletion. This renders them problematic for corroborating our findings in vivo. Moreover, complete loss of
function of FECH is incompatible with survival (Magness et al., 2002). For these reasons, for in vivo validation
we employed here an acute model of FECH blockade using local administration of NMPP intravitreally. None-
theless, this FECH inhibition in vivo had energetic effects in the retina similar to those seen on retinal and
choroidal ECs cultured in vitro. However, an important limitation is that this technique cannot distinguish the
energetic profiles of ECs from other cell types present in the retina.
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Supplemental Figures 
 
Figure S1. Mitochondrial morphometric analysis and PPIX levels in HRECs treated with NMPP, Related 
to Figure 1. 
(A) PPIX levels quantified by ultra-performance liquid chromatography in HRECs treated with NMPP. 
Representative cells depicting particle analysis for measuring mitochondria. (B, C) Representative slice 
from Z-stack images showing threshold intensity set for DMSO and NMPP treated HRECs. (D, E) 
Representative slice from Z-stack images showing outlines of assessed mitochondria. (F, G) Correlation 
of form factor versus aspect ratio under DMSO and NMPP treatments for the representative cells shown 
above. Scale bars = 10 µm. 
Figure S2. FCCP titration and cell energy phenotype of HRECs and RF/6A cells, Related to Transparent 
Methods and Figure 4.
Optimization of uncoupler FCCP concentration that produces maximal respiration in ocular endothelial 
cells. Oxygen consumption rate (OCR) traces of (A) HRECs and (B) RF/6A cells. 2´104 cells seeded. 
Mean ± SEM, n=3. Cellular energetic phenotype profiles under metabolic stress of (C) HRECs and (D) 
RF/6A cells. Open box indicates baseline phenotype, filled box indicates stressed phenotype. 
Representative plots of three independent experiments. Some error bars are too small to be seen. (E, F) 
% stressed OCR and ECAR produced over 100% baseline OCR and ECAR. Mean ± SEM, n=3; **p<0.01, 
****p<0.0001, two-tailed unpaired Student’s t-test. 
Figure S3. Optimizing cell seeding density, Related to Transparent Methods and Figure 4. 
(A) Representative images from three independent experiments of HRECs. Scale bar = 500 µm. (B) 
Related OCR traces, (C) basal respiration, and (D) maximal respiration. Mean ± SEM, n=3; ns, not 
significant, **p<0.01, ANOVA with Tukey’s post-hoc tests.
Figure S4. FECH blockade caused mitochondrial defects in RF/6A cells, Related to Figures 1 and 2. 
(A) RF/6A cells labeled with mitoSox ROS were assessed using flow cytometry. Representative
fluorescence peaks. (B) Quantification of cells positive for red fluorescence. ****p<0.0001 vs. DMSO,
unpaired Student’s t-test. (C) RF/6A cells stained with JC-1 dye showing green monomers and red
aggregates under NMPP treatment. (D) Representative dot plots of FL1 versus FL2 channel measuring
red and green fluorescence using flow cytometry after NMPP treatment. Red and green arrows indicate
quadrants expressing FL1-red and FL2-green fluorescent cells. (E) Quantification of red:green
fluorescence from flow experiment. *p<0.05 vs. untreated, one-way ANOVA with Tukey’s post hoc tests.
Bar graphs indicate mean ± SEM, n=3; Scale bars = 20 µm.
 
Figure S5. Loss of heme decreases transcription of nuclear encoded CcO but has no effect on activities 
of complexes I-III, Related to Figure 3. 
(A) mRNA quantification of genes encoding components of ETC complexes I-IV (B-D) HRECs treated 
with NMPP were assessed for activities of (B) complex I, (C) complex II and (D) complex III. Bar graphs 















































































































Figure S6. FECH inhibition decreases mitochondrial respiration and CcO expression, which is rescued by 
hemin in RF/6A cells, Related to Figures 3 and 4. 
(A) RF/6A cells treated with NMPP were blotted for nuclear-encoded CcO subunit 1 (COX4I1) with (B) 
quantification as shown. (C, D) RF/6A cells treated with 100 µM NMPP show rescue of CcO subunit 1 
protein levels after hemin supplementation. (E) Representative OCR kinetic traces for RF/6As under 
NMPP chemical inhibition. (F) Basal respiration, (G) maximal respiration, (H) OCR-linked ATP production, 
and (I) spare respiratory capacity were calculated based on OCR curves for the respective treatment 
group. Bar graphs indicate mean ± SEM, n=3; *p<0.05, ***p<0.001, ****p<0.0001, (D) one-way ANOVA 







































































































































































































Figure S7. Loss of heme through ALAD blockade reduces mitochondrial respiration, Related to Figures 3 
and 4. 
(A) HRECs treated with succinylacetone were immunoblotted for Complexes I-V as indicated. (B) 
Quantification of the blots was graphed as shown relative to control. (C) OCR kinetic traces for HRECs 
under succinylacetone treatment. (D) Basal respiration, (E) maximal respiration, (F) OCR-linked ATP 
production, and (G) spare respiratory capacity were calculated based on OCR curves for the respective 
treatment group. Representative OCR curve of three individual experiments. Bar graphs indicate mean ± 
SEM, n=3; *p<0.05, **p<0.01, unpaired Student’s t-test.  
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Experimental Model and Subject Details 
Cell Culture 
Human primary retinal microvascular endothelial cells (HRECs) and Attachment Factor were purchased 
from Cell Systems (Kirkland, WA, USA). Female HRECs were grown in endothelial growth medium 
(EGM-2) and used between passages 4 and 8. EGM-2 was prepared by combining components of an 
EGM-2 “bullet kit” (Cat no. CC-4176) and endothelial basal medium (EBM, Lonza, Walkersville, MD, USA; 
Cat No. CC-3156). As primary cells, these were not subject to authentication. Rhesus macaque choroidal 
endothelial (RF/6A) cells were obtained from ATCC (Manassas, VA, USA) and grown in Eagle’s Minimum 
Essential Medium (EMEM, ATCC Cat No. 30-2003) supplemented with 10% fetal bovine serum (FBS, 
PAA Laboratories, Etobicoke, ON, Canada; Cat No. A15-751). Since short tandem repeat profiles are not 
available for Rhesus, these cells were not authenticated after receipt from the supplier, and sex was not 
reported. All cells were grown at 37°C, 5% CO2, 100% humidity and tested for mycoplasma contamination 
regularly. N-methyl protoporphyrin (NMPP) was purchased from Frontier Scientific (Logan, Utah, USA), 
prepared in DMSO, and applied to cells at 1 µM or 10 µM (as indicated) for 48 hours. FECH siRNA 
(SASI_Hs01_00052189 and SASI_Hs01_00052190) was purchased from Sigma and MISSION® siRNA 
Universal from Sigma was used as a negative siRNA control. Succinylacetone (Sigma-Aldrich, Saint 
Louis, MO, USA) was prepared in sterile water and used at 1 mM final well concentration for 24 hours 
and water was used as vehicle control. 
Animals 
Animal studies were approved by the Indiana University School of Medicine Institutional Animal Care and 
Use Committee, and were consistent with the Association for Research in Vision and Ophthalmology 
Statement for the Use of Animals in Ophthalmic and Visual Research. C57BL/6J wild-type, healthy 
female mice, 8 weeks of age were purchased from Jackson Laboratories and group housed under 
standard conditions. NMPP at 10 µM final vitreous concentration was injected intravitreally into naïve 
mice under ketamine/xylazine anesthesia as described (Sulaiman et al., 2016), and 24 hrs post-injection, 
animals were euthanized, and retinas were immediately isolated from the animals and processed for the 
energetics experiment.  
Method Details 
Protoporphyrin IX quantification 
Protoporphyrin IX (PPIX) analysis was performed at the Iron and Heme Core facility at the University of 
Utah. Cells were washed with PBS, pelleted, and stored frozen at -80°C. The cells were suspended in 50 
mM potassium phosphate pH 7.4 and homogenized by sonication. 200 µL extraction solvent 
(EtOAc:HOAc, 4:1) was slowly added to 50 µL concentration-adjusted sample and shaken. The mixture 
was centrifuged at 16000xg for 0.5 min and the supernatant was collected. About 10 µL of the 
supernatant solution above was injected into a Waters Acquity ultra performance liquid chromatography 
(UPLC) system with an Acquity UPLC BEH C18, 1.7 µm, 2.1 x 100 mm column. PPIX was detected at 
404 nm excitation and 630 nm emission. Solvent A was 0.2% aqueous formic acid while Solvent B was 
0.2% formic acid in methanol. The flow rate was kept at 0.40 mL per minute and the column maintained 
at 60˚C for the total run time of 7 min. The following successive linear gradient settings for run time in 
minutes versus Solvent A were as follows: 0.0, 80%; 2.5, 1%; 4.5, 1%; 5.0, 80%. 
Mitochondrial morphology  
Cells were plated on 35 mm coverslip bottom dishes. HRECs were stained using MitoTracker Green 
(Thermo Fisher, Cat no M7514) at 200 nM for 10 minutes in the dark at 37°C. Imaging was performed 
immediately following staining using an LSM700 confocal microscope (Zeiss, Thornwood, NY, USA) 
under a 63× oil immersion lens and acquired Z-stacked images were analyzed using ImageJ software 
(Trudeau et al., 2010). Briefly, individual cells were selected and particle analysis was performed to 
determine form factor (perimeter2/4𝜋*area) and aspect ratio (length of major and minor axes). 
Mitochondria of 12 cells per condition were analyzed and the mean per cell was considered for further 
statistical tests.  
Mitochondrial membrane potential assessment 
Membrane potential (ΔΨm) was measured with 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolcarbo 
cyanine iodide (JC-1) (Santa Cruz, Santa Cruz, CA, USA) dye (Perelman et al., 2012). Cells were stained 
with JC-1 dye at 5 µg/mL final concentration for 10 minutes in the dark at 37°C. Cells were washed with 
1× HBSS and prepared for flow cytometry (FACSCalibur, BD Biosciences, San Jose, CA) in Fluorobrite 
DMEM. JC-1 dye after accumulation in mitochondria forms red aggregates and green monomers that emit 
fluorescence at 590 nm and 510 nm respectively. For live imaging, cells grown in coverslip bottom 35mm 
dishes were stained and imaged using the Zeiss confocal microscope under a 63× oil immersion 
objective.  
Mitochondrial ROS measurement 
Cells were labeled with MitoSox ROS (Thermo Fisher Scientific) dye at 5 µM final concentration for 10 
minutes in the dark at 37°C using phenol red-free Fluorobrite DMEM. Cells were washed and stained with 
Hoechst 33342 stain for 10 minutes at room temperature. For flow cytometry, cells were labeled with dye 
at 1 µM final concentration, incubated in the dark at 37°C and immediately loaded for ROS fluorescence 
detection in the FL-2 channel using flow cytometry (Kauffman et al., 2016).  
mRNA quantification using qPCR 
RNA was isolated using Trizol reagent and 1 µg RNA was used for cDNA synthesis, made using iScript 
cDNA synthesis kit from Bio Rad (Cat no. 1708897, Hercules, CA, USA). TaqMan probes for MFN2 
(Hs00208382_m1), DNM1L (Hs01552605_m1), OPA1 (Hs01047013_m1), FECH (Hs01555261_m1), 
NDUFS1 (Hs00192297_m1), SDHA (Hs00188166_m1), UQCRQ (Hs00429571_g1), MT-CO1 
(Hs02596864_g1), and COX4I1 (Hs00971639_m1) were purchased from Thermo Fisher Scientific 
(Pittsburgh, PA, USA). qPCR was performed using Fast Advanced Master Mix, TaqMan probes, and a 
ViiA7 thermal cycler (Applied Biosystems). Gene expression was determined using ΔΔCt method and 
HPRT (Hs02800695_m1) as housekeeping control and normalized to individual sample controls. 
Immunoblotting 
Cells were lysed in RIPA buffer (Sigma-Aldrich, St. Louis, MO, USA, Cat no. R0278) and processed for 
protein quantification followed by SDS-PAGE. For ETC proteins, total OXPHOS Rodent WB Antibody 
Cocktail (Abcam, ab110413, Cambridge, MA, USA) at 1:250 dilution was used. CcO nuclear-encoded 
subunit 1 (COX4I1) antibody was purchased from Thermo Fisher Scientific (Cat no. PA5-19471, 
Pittsburgh, PA, USA) and used at 1:1000 dilution. b-actin antibody was purchased from Sigma (Cat no. 
A5441) and used at 1:2000 dilution. FECH antibody was purchased from LifeSpan BioSciences (Seattle, 
WA, USA, Cat no LS C409953) and used at 1:500 dilution prepared in 5% BSA solution. 
Chemiluminescent reagent ECL Prime was purchased from GE Healthcare (Buckinghamshire, UK, Cat 
no. RPN2232). 
Complexes I-IV activity assays 
For complex I activity, HRECs treated with NMPP (10 µM) or DMSO were harvested and processed using 
a kit (Abcam, Cambridge, MA, USA, Cat no. ab109721) according to manufacturer’s instructions. Briefly, 
250 µg of protein lysates were loaded into plates pre-coated with immobilized complex I and the oxidation 
of NADH to NAD+ was measured as the increase in absorbance at 450 nm, read on a Synergy H1 plate 
reader (BioTek, Winooski, VT, USA). Complex II enzyme activity was measured using an assay kit 
(Abcam, Cambridge, MA, USA, Cat no. ab109908) following manufacturer’s instructions. Cell lysates from 
HRECs treated with either DMSO or NMPP (10 µM) were processed and 250 µg protein was loaded into 
plates coated with anti-complex II antibody. The activity of complex II was determined by measuring the 
production of ubiquinol coupled to the dye 2,6- dichlorophenolindophenol as a reduction in absorbance at 
600 nm. For complex III activity, cell lysates from NMPP (10 µM) or DMSO treated HRECs were 
processed using complex II + III enzyme assay kit (Abcam, Cambridge, MA, USA, Cat no. ab109905) 
according to manufacturer’s instructions. Complex III activity was determined as a gain in absorbance 
from the reaction of oxidized cytochrome c to the reduced form at 550 nm. ELISA was performed on cell 
lysates treated using Complex IV ELISA kit (Abcam, Cambridge, MA, USA, Cat no. ab109909) following 
manufacturer’s instructions. Briefly, 10 µg protein was loaded into plates coated with CcO antibody and 
oxidation of reduced cytochrome c by the immunocaptured CcO from the sample was measured, using 
absorbance at 550 nm. Kinetic reads were obtained and slopes directly correlating to enzyme activity 
were determined. Total amount of CcO was also assessed on the same samples. 
Hemin rescue 
For hemin rescue experiments, hemin (Sigma-Aldrich, Cat no H9039) 10 µM (final well concentration) 
was freshly prepared in DMSO. Cells pretreated with NMPP were supplemented with hemin in EBM2 
containing 0.2% FBS for 6 hrs, followed by harvesting and processing for immunoblotting or ELISA. 
FCCP titration, cell density determination, and cell energy phenotype 
For determining optimal FCCP concentration, two ranges of FCCP were used (Figure S2A, B). Low range 
concentrations of 0.125, 0.25 and 0.5 µM and high range concentrations of 0.5, 1 and 2 µM were used for 
titration. We found 1 µM and 0.125 µM suitable for HRECs and RF/6A cells respectively. Similarly, for 
identification of appropriate cell seeding density to determine OCR and ECAR, cells at 5´103, 2´104 and 
4´104 cells per well were plated overnight, and photographed using an EVOS fl digital microscope, 
followed by Seahorse XF analyses described below. 
For assessment of cellular energy phenotype, cells (2´104 per well) were grown, as indicated, overnight 
followed by assessment of metabolic phenotype using the Seahorse XFp Cell Energy Phenotype test kit 
(Cat. No. 103275-100). Stressor mix was prepared by combining 1 µM oligomycin and 0.125 or 1 µM 
FCCP. Cells were incubated in base medium containing glutamine, sodium pyruvate and glucose for 1 
hour in a room air incubator prior to measurements. Five cycles of readings were taken after the injection 
of stressor mix on the cells and kinetic traces indicating OCR and ECAR were produced in tandem. 
Mitochondrial energetics 
For measuring mitochondrial function, oxygen consumption rate (OCR) was measured using the 
Seahorse XFp Cell Mito Stress test kit (Cat No. 103010-100) (Figure S3) (Dranka et al., 2011) at the 
Indiana University School of Medicine Angio BioCore. Cells (2´104 per well) treated with NMPP (10 µM) 
or succinyl acetone (1 mM) were seeded overnight in XFp miniplates. Sensor cartridges were hydrated 
overnight in XF calibrant in a room air incubator. Next day, XF Base assay medium was prepared by 
addition of 5.5 mM glucose and 0.61 mM sodium pyruvate. For HRECs, 3.2 mM L-glutamine was used, 
while for RF/6A cells 1.6 mM concentration was used as per their respective routine culture medium 
compositions. Unbuffered base medium was filter sterilized followed by pH adjustment to 7.4 using 0.2 N 
NaOH solution. Cells were rinsed with base medium twice to remove overnight culture medium and this 
was replaced with base assay medium. Cells were incubated for a minimum of 1 hour in a room air 
incubator before proceeding with the assay. Mitochondrial inhibitors at final well concentrations of 1 µM 
oligomycin, 0.125 µM (for RF/6A cells) or 1 µM FCCP (for HRECs) and 0.5 µM rotenone/antimycin A were 
prepared using freshly buffered base medium. Mitochondrial inhibitors were then loaded into the hydrated 
sensor cartridges. After incubating cells in a room air incubator, XFp miniplates and the sensor cartridges 
were loaded into the instrument and OCR readings were determined using the XFp analyzer. The assay 
program was set up to measure three cycles of oligomycin followed by FCCP and a final injection of 
rotenone/antimycin A injected at indicated times. OCR in response to serial injections of oligomycin, 
FCCP and rotenone/antimycin mixture were recorded real-time in a kinetic assay. 
 
For retinal ex vivo OCR measurements, protocols were adapted as previously described (Joyal et al., 
2016; Kooragayala et al., 2015). Briefly, eyes were enucleated and retina was isolated from the posterior 
cup. Retinal punches (1 mm diameter) were dissected from an area adjacent to optic nerve to minimize 
variability in retinal thickness. Retinal punches were incubated in Seahorse XF DMEM Medium pH 7.4 
containing 5 mM HEPES supplemented with 12 mM glucose and 2 mM L-glutamine for 1 hour in a room 
air incubator at 37°C. For OCR measurement, 0.5 µM FCCP and 0.5 µM rotenone/antimycin A were 
injected and OCR readings were determined. 
Glycolytic function 
Glycolytic parameters were measured using the Seahorse XF Glycolysis Stress test kit (Cat No. 103020-
100). Cells (2´104 per well) were grown overnight followed by glucose starvation in assay medium 
containing sodium pyruvate and glutamine for 1 hour in a room air incubator. Compounds modulating 
glycolysis were prepared using the same assay medium. Glucose at a final well concentration of 10 mM, 
oligomycin at 1µM and 2-deoxyglucose at 50 mM were loaded onto ports of the hydrated sensor cartridge 
followed by measurement of extracellular acidification rate (ECAR) using the XFp analyzer. 
Quantification and Statistical Analysis 
All Seahorse kinetic traces were analyzed using Wave 2.4 software (Agilent) and GraphPad Prism v. 8.0. 
FCS files for flow cytometry were analyzed using FlowJo v10. Comparisons between groups were 
performed with either unpaired, two-tailed Student’s t-test or one-way ANOVA with Tukey’s post-hoc tests 
as indicated. p values < 0.05 were considered statistically significant. Mean±SEM shown for all graphs 
unless indicated otherwise; n is listed in figure legends.  
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